Compendium of Cancer Genome Aberrations

HAEM5:High grade B-cell lymphoma with 11q aberrations: Difference between revisions

[checked revision][checked revision]
← Older editNewer edit →
VisualWikitext
No edit summary
Removed old template contents
Line 1: Line 1:
{{DISPLAYTITLE:High grade B-cell lymphoma with 11q aberrations}}
{{DISPLAYTITLE:High grade B-cell lymphoma with 11q aberrations}}
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]


{{Under Construction}}
{{Under Construction}}


<blockquote class='blockedit'>{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Burkitt-Like Lymphoma with 11q Aberration]].
<blockquote class="blockedit">{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Burkitt-Like Lymphoma with 11q Aberration]].
}}</blockquote>
}}</blockquote>


Line 39: Line 40:
|}
|}


==Definition / Description of Disease==
Put your text here <span style="color:#0070C0">(''Instructions: Brief description of approximately one paragraph - include disease context relative to other WHO classification categories, diagnostic criteria if applicable, and differential diagnosis if applicable. Other classifications can be referenced for comparison.'') </span>
==Synonyms / Terminology==
Put your text here <span style="color:#0070C0">(''Instructions: Include currently used terms and major historical ones, adding “(historical)” after the latter.'') </span>
==Epidemiology / Prevalence==
*Males>females, with estimated ratio of 2.75:1 in one cohort<ref name=":7">{{Cite journal|last=Wagener|first=Rabea|last2=Seufert|first2=Julian|last3=Raimondi|first3=Francesco|last4=Bens|first4=Susanne|last5=Kleinheinz|first5=Kortine|last6=Nagel|first6=Inga|last7=Altmüller|first7=Janine|last8=Thiele|first8=Holger|last9=Hübschmann|first9=Daniel|date=2019-02-28|title=The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma|url=https://ashpublications.org/blood/article/133/9/962/260647/The-mutational-landscape-of-Burkittlike-lymphoma|journal=Blood|language=en|volume=133|issue=9|pages=962–966|doi=10.1182/blood-2018-07-864025|issn=0006-4971|pmc=PMC6396176|pmid=30567752}}</ref>
*Seems to have no racial predilection
*Increased incidence in post-transplant/immunodeficient individuals<ref name=":8">{{Cite journal|last=Wang|first=Jing|last2=Ma|first2=Li|last3=Guo|first3=Jianghong|last4=Xi|first4=Yanfeng|last5=Xu|first5=Enwei|date=2021-03-16|title=Burkitt-like lymphoma with 11q aberration in a patient with AIDS and a patient without AIDS: Two cases reports and literature review|url=https://www.degruyter.com/document/doi/10.1515/med-2021-0246/html|journal=Open Medicine|language=en|volume=16|issue=1|pages=428–434|doi=10.1515/med-2021-0246|issn=2391-5463|pmc=PMC7967281|pmid=33763601}}</ref>, but never EBV-associated<ref name=":7" /> <ref name=":9">{{Cite journal|last=Kim|first=Jee Ah|last2=M.D|last3=Kim|first3=Hyun-Young|last4=M.D|last5=Kim|first5=Seok Jin|last6=M.D|last7=Kim|first7=Hee-Jin|last8=M.D|last9=Kim|first9=and Sun-Hee|date=2021-11-01|title=A Case of Burkitt-Like Lymphoma With 11q Aberration With HIV Infection in East Asia and Literature Review|url=https://www.annlabmed.org/journal/view.html?doi=10.3343/alm.2021.41.6.593|journal=Annals of Laboratory Medicine|language=en|volume=41|issue=6|pages=593–597|doi=10.3343/alm.2021.41.6.593|pmc=PMC8203433|pmid=34108287}}</ref>
*Immunodeficiency can be congenital, HIV-associated, or iatrogenic in setting of transplant<ref name=":9" /> <ref>{{Cite journal|last=Wang|first=Jing|last2=Ma|first2=Li|last3=Guo|first3=Jianghong|last4=Xi|first4=Yanfeng|last5=Xu|first5=Enwei|date=2021-01-01|title=Burkitt-like lymphoma with 11q aberration in a patient with AIDS and a patient without AIDS: Two cases reports and literature review|url=https://www.degruyter.com/document/doi/10.1515/med-2021-0246/html|journal=Open Medicine|language=en|volume=16|issue=1|pages=428–434|doi=10.1515/med-2021-0246|issn=2391-5463|pmc=PMC7967281|pmid=33763601}}</ref>
*Age range: 4<ref name=":7" />-82<ref>{{Cite journal|last=Moshref Razavi|first=Habib|last2=Hrynchak|first2=Monica|date=2019-01-24|title=Unusual presentation of Burkitt-like lymphoma with 11q aberration in an elderly patient|url=https://ashpublications.org/blood/article/133/4/381/272765/Unusual-presentation-of-Burkittlike-lymphoma-with|journal=Blood|language=en|volume=133|issue=4|pages=381–381|doi=10.1182/blood-2018-08-864728|issn=0006-4971}}</ref>
**median age: 13.9 in a study limited to pediatric patient cohort <ref name=":4">{{Cite journal|last=Au‐Yeung|first=Rex K. H.|last2=Arias Padilla|first2=Laura|last3=Zimmermann|first3=Martin|last4=Oschlies|first4=Ilske|last5=Siebert|first5=Reiner|last6=Woessmann|first6=Wilhelm|last7=Burkhardt|first7=Birgit|last8=Klapper|first8=Wolfram|date=2020-09|title=Experience with provisional WHO‐entities large B‐cell lymphoma with IRF4 ‐rearrangement and Burkitt‐like lymphoma with 11q aberration in paediatric patients of the NHL‐BFM group|url=https://onlinelibrary.wiley.com/doi/10.1111/bjh.16578|journal=British Journal of Haematology|language=en|volume=190|issue=5|pages=753–763|doi=10.1111/bjh.16578|issn=0007-1048}}</ref>, 49.5<ref name=":1" />
**mean age: 15<ref name=":6">{{Cite journal|last=Gonzalez-Farre|first=Blanca|last2=Ramis-Zaldivar|first2=Joan Enric|last3=Salmeron-Villalobos|first3=Julia|last4=Balagué|first4=Olga|last5=Celis|first5=Verónica|last6=Verdu-Amoros|first6=Jaime|last7=Nadeu|first7=Ferran|last8=Sábado|first8=Constantino|last9=Ferrández|first9=Antonio|date=2019-09|title=Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma|url=http://www.haematologica.org/lookup/doi/10.3324/haematol.2018.207928|journal=Haematologica|language=en|volume=104|issue=9|pages=1822–1829|doi=10.3324/haematol.2018.207928|issn=0390-6078|pmc=PMC6717587|pmid=30733272}}</ref>,15.5<ref name=":7" />
==Clinical Features==
{| class="wikitable"
|'''Signs and Symptoms'''
|Small, localized lymphadenopathy (most common) <ref name=":6" />bulky tumors (>7-20 cm) possible, mostly abdominal <ref name=":0" />
1/3 of pediatric patients B-symptoms (weight loss, fever, night sweats) <ref name=":4" />
|-
|'''Laboratory Findings'''
|LDH elevation possible, generally below 500 <ref name=":0" /> <ref name=":4" />
|}
==Sites of Involvement==
*Nodal involvement <ref name=":6" />
**cervical and abdominal lymphadenopathy predominant, with axillary, inguinal, tonsillar, and submandibular less commonly reported <ref name=":9" /> <ref name=":7" /> <ref name=":8" /> <ref name=":6" /> <ref name=":0" />
**less common sites such as testes, parotid reported in association with immunodeficient patients <ref name=":9" />
*Rare bone marrow involvement<ref name=":2">{{Cite journal|last=Salaverria|first=Itziar|last2=Martin-Guerrero|first2=Idoia|last3=Wagener|first3=Rabea|last4=Kreuz|first4=Markus|last5=Kohler|first5=Christian W.|last6=Richter|first6=Julia|last7=Pienkowska-Grela|first7=Barbara|last8=Adam|first8=Patrick|last9=Burkhardt|first9=Birgit|date=2014-02-20|title=A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma|url=https://ashpublications.org/blood/article/123/8/1187/32820/A-recurrent-11q-aberration-pattern-characterizes-a|journal=Blood|language=en|volume=123|issue=8|pages=1187–1198|doi=10.1182/blood-2013-06-507996|issn=0006-4971|pmc=PMC3931189|pmid=24398325}}</ref>
*CNS involvement is rare <ref name=":9" /> <ref name=":7" /> <ref name=":8" /> <ref name=":6" /> <ref name=":0" />
==Morphologic Features==
*Medium to large sheets of B-cells frequently with starry-sky background
*Diverse, having been morphologically classified as the following: <ref name=":4" /> <ref name=":6" />
**BLL, including atypical
**HGBCL, NOS
**DLBCL
*Course and increased number of apoptotic bodies (5-9) per macrophage<ref name=":1">{{Cite journal|last=Horn|first=Heike|last2=Kalmbach|first2=Sabrina|last3=Wagener|first3=Rabea|last4=Staiger|first4=Annette M.|last5=Hüttl|first5=Katrin|last6=Mottok|first6=Anja|last7=Bens|first7=Susanne|last8=Traverse-Glehen|first8=Alexandra|last9=Fontaine|first9=Juliette|date=2021-03|title=A Diagnostic Approach to the Identification of Burkitt-like Lymphoma With 11q Aberration in Aggressive B-Cell Lymphomas|url=https://journals.lww.com/10.1097/PAS.0000000000001613|journal=American Journal of Surgical Pathology|language=en|volume=45|issue=3|pages=356–364|doi=10.1097/PAS.0000000000001613|issn=0147-5185}}</ref>
*Cytologic features often more blastoid <ref name=":6" />
==Immunophenotype==
Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table. Do not delete table.'') </span>
{| class="wikitable sortable"
|-
!Finding!!Marker
|-
|Positive (universal)||<span class="blue-text">EXAMPLE:</span> CD1
|-
|Positive (subset)||<span class="blue-text">EXAMPLE:</span> CD2
|-
|Negative (universal)||<span class="blue-text">EXAMPLE:</span> CD3
|-
|Negative (subset)||<span class="blue-text">EXAMPLE:</span> CD4
|}
<blockquote class='blockedit'>{{Box-round|title=v4:Immunophenotype|The content below was from the previous version of the page. Please incorporate above.}}</blockquote>
{| class="wikitable sortable"
|-
!Flow Findings!!Marker
|-
|Positive (universal)||CD10, CD20, CD19, CD22, BCL6 <ref name=":0" />
|-
|Positive (subset)||CD16/CD56 (present in 60%), CD8 (present in 40%) <ref name=":0" />
|-
|Negative (universal)||CD5, CD11C, CD23, CD200, BCL2 <ref name=":0" />
|-
|Negative (subset)||CD38 bright (absent 90%) <ref name=":0" />
|}
Statistically significant differences in flow cytometry of BLL11q as compared to myc-positive Burkitt Lymphoma:<ref name=":0">{{Cite journal|last=Rymkiewicz|first=Grzegorz|last2=Grygalewicz|first2=Beata|last3=Chechlinska|first3=Magdalena|last4=Blachnio|first4=Katarzyna|last5=Bystydzienski|first5=Zbigniew|last6=Romejko-Jarosinska|first6=Joanna|last7=Woroniecka|first7=Renata|last8=Zajdel|first8=Michalina|last9=Domanska-Czyz|first9=Katarzyna|date=2018-05|title=A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration|url=http://www.nature.com/articles/modpathol2017186|journal=Modern Pathology|language=en|volume=31|issue=5|pages=732–743|doi=10.1038/modpathol.2017.186|issn=0893-3952}}</ref>
*less frequent CD45 depression <ref name=":0" />
*less frequent CD38 bright expression (10% as opposed to 91% in myc-postive BL) <ref name=":0" />
*CD16/CD56 (NK differentiation) positivity (60% of time as opposed to 0% in myc-positive BL) <ref name=":0" />
*CD 8 expression (40% as opposed to 4% in myc-positive BL) <ref name=":0" />
Immunohistochemistry:
*GCB phenotype <ref name=":4" /> <ref name=":1" /><ref name=":6" />
*Ki67 usually >90% <ref name=":4" /> <ref name=":0" /><ref name=":6" /> <ref name=":7" /> <ref name=":1" />
*LMO2 expression (46% to 70% as compared to 0% in myc-positive BL)<ref name=":6" /><ref name=":0" />
*MYC may be positive if using a 40% MYC<ref name=":6" />
<blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
==WHO Essential and Desirable Genetic Diagnostic Criteria==
==WHO Essential and Desirable Genetic Diagnostic Criteria==
<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
Line 181: Line 85:
==Individual Region Genomic Gain/Loss/LOH==
==Individual Region Genomic Gain/Loss/LOH==


The table below represents the smallest reported minimal lost region and smallest reported minimal gain region. Other larger MGR and MLR have been reported.<ref name=":2" /> <ref>{{Cite journal|last=Ferreiro|first=J. F.|last2=Morscio|first2=J.|last3=Dierickx|first3=D.|last4=Marcelis|first4=L.|last5=Verhoef|first5=G.|last6=Vandenberghe|first6=P.|last7=Tousseyn|first7=T.|last8=Wlodarska|first8=I.|date=2015-07-01|title=Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern|url=http://www.haematologica.org/cgi/doi/10.3324/haematol.2015.124305|journal=Haematologica|language=en|volume=100|issue=7|pages=e275–e279|doi=10.3324/haematol.2015.124305|issn=0390-6078|pmc=PMC4486241|pmid=25795716}}</ref>
The table below represents the smallest reported minimal lost region and smallest reported minimal gain region. Other larger MGR and MLR have been reported.<ref name=":2">{{Cite journal|last=Salaverria|first=Itziar|last2=Martin-Guerrero|first2=Idoia|last3=Wagener|first3=Rabea|last4=Kreuz|first4=Markus|last5=Kohler|first5=Christian W.|last6=Richter|first6=Julia|last7=Pienkowska-Grela|first7=Barbara|last8=Adam|first8=Patrick|last9=Burkhardt|first9=Birgit|date=2014-02-20|title=A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma|url=https://ashpublications.org/blood/article/123/8/1187/32820/A-recurrent-11q-aberration-pattern-characterizes-a|journal=Blood|language=en|volume=123|issue=8|pages=1187–1198|doi=10.1182/blood-2013-06-507996|issn=0006-4971|pmc=PMC3931189|pmid=24398325}}</ref> <ref>{{Cite journal|last=Ferreiro|first=J. F.|last2=Morscio|first2=J.|last3=Dierickx|first3=D.|last4=Marcelis|first4=L.|last5=Verhoef|first5=G.|last6=Vandenberghe|first6=P.|last7=Tousseyn|first7=T.|last8=Wlodarska|first8=I.|date=2015-07-01|title=Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern|url=http://www.haematologica.org/cgi/doi/10.3324/haematol.2015.124305|journal=Haematologica|language=en|volume=100|issue=7|pages=e275–e279|doi=10.3324/haematol.2015.124305|issn=0390-6078|pmc=PMC4486241|pmid=25795716}}</ref>


{| class="wikitable sortable"
{| class="wikitable sortable"
Line 249: Line 153:
|unknown
|unknown
|-
|-
|5q21.3q32 gain and 6q12.1-q21 loss <ref name=":5">{{Cite journal|last=Asadbeigi|first=Sepideh N.|last2=Deel|first2=Chelsey D.|date=2020-09-08|title=Burkitt-Like Lymphoma with 11q Aberration: A Case Report and Review of a Rare Entity|url=https://www.hindawi.com/journals/crihem/2020/8896322/|journal=Case Reports in Hematology|language=en|volume=2020|pages=e8896322|doi=10.1155/2020/8896322|issn=2090-6560|pmc=PMC7495152|pmid=32963851}}</ref><ref name=":6" />
|5q21.3q32 gain and 6q12.1-q21 loss <ref name=":5">{{Cite journal|last=Asadbeigi|first=Sepideh N.|last2=Deel|first2=Chelsey D.|date=2020-09-08|title=Burkitt-Like Lymphoma with 11q Aberration: A Case Report and Review of a Rare Entity|url=https://www.hindawi.com/journals/crihem/2020/8896322/|journal=Case Reports in Hematology|language=en|volume=2020|pages=e8896322|doi=10.1155/2020/8896322|issn=2090-6560|pmc=PMC7495152|pmid=32963851}}</ref><ref name=":6">{{Cite journal|last=Gonzalez-Farre|first=Blanca|last2=Ramis-Zaldivar|first2=Joan Enric|last3=Salmeron-Villalobos|first3=Julia|last4=Balagué|first4=Olga|last5=Celis|first5=Verónica|last6=Verdu-Amoros|first6=Jaime|last7=Nadeu|first7=Ferran|last8=Sábado|first8=Constantino|last9=Ferrández|first9=Antonio|date=2019-09|title=Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma|url=http://www.haematologica.org/lookup/doi/10.3324/haematol.2018.207928|journal=Haematologica|language=en|volume=104|issue=9|pages=1822–1829|doi=10.3324/haematol.2018.207928|issn=0390-6078|pmc=PMC6717587|pmid=30733272}}</ref>
|unknown
|unknown
|unknown
|unknown
|unknown
|unknown
|Noted to be recurrently concomitantly present with the characteristic proximal duplications and deletions that define BLL, 11q.<ref name=":5" />
|Noted to be recurrently concomitantly present with the characteristic proximal duplications and deletions that define BLL, 11q.<ref name=":5" />
|}Notably, no 1q21 abnormalities were found in myc-negative, 11q positive cases. <ref name=":1" /><ref name=":6" />
|}Notably, no 1q21 abnormalities were found in myc-negative, 11q positive cases. <ref name=":1">{{Cite journal|last=Horn|first=Heike|last2=Kalmbach|first2=Sabrina|last3=Wagener|first3=Rabea|last4=Staiger|first4=Annette M.|last5=Hüttl|first5=Katrin|last6=Mottok|first6=Anja|last7=Bens|first7=Susanne|last8=Traverse-Glehen|first8=Alexandra|last9=Fontaine|first9=Juliette|date=2021-03|title=A Diagnostic Approach to the Identification of Burkitt-like Lymphoma With 11q Aberration in Aggressive B-Cell Lymphomas|url=https://journals.lww.com/10.1097/PAS.0000000000001613|journal=American Journal of Surgical Pathology|language=en|volume=45|issue=3|pages=356–364|doi=10.1097/PAS.0000000000001613|issn=0147-5185}}</ref><ref name=":6" />
==Gene Mutations (SNV/INDEL)==
==Gene Mutations (SNV/INDEL)==


Line 346: Line 250:
==Genetic Diagnostic Testing Methods==
==Genetic Diagnostic Testing Methods==


*Conventional cytogenetics (karyotyping) + FISH using MYC break-apart probe to rule out MYC translocation <ref name=":5" /> <ref name=":9" />
*Conventional cytogenetics (karyotyping) + FISH using MYC break-apart probe to rule out MYC translocation <ref name=":5" /> <ref name=":9">{{Cite journal|last=Kim|first=Jee Ah|last2=M.D|last3=Kim|first3=Hyun-Young|last4=M.D|last5=Kim|first5=Seok Jin|last6=M.D|last7=Kim|first7=Hee-Jin|last8=M.D|last9=Kim|first9=and Sun-Hee|date=2021-11-01|title=A Case of Burkitt-Like Lymphoma With 11q Aberration With HIV Infection in East Asia and Literature Review|url=https://www.annlabmed.org/journal/view.html?doi=10.3343/alm.2021.41.6.593|journal=Annals of Laboratory Medicine|language=en|volume=41|issue=6|pages=593–597|doi=10.3343/alm.2021.41.6.593|pmc=PMC8203433|pmid=34108287}}</ref>
*Chromosomal microarray analysis <ref name=":6" /> <ref name=":9" />
*Chromosomal microarray analysis <ref name=":6" /> <ref name=":9" />


Line 403: Line 307:


*Look for 11q aberration if Myc negative lymphoma with morphology reminiscent of BL, DLBCL, or HGBCL <ref name=":6" />
*Look for 11q aberration if Myc negative lymphoma with morphology reminiscent of BL, DLBCL, or HGBCL <ref name=":6" />
*Attend to associated chromosomal and mutational abnormalities of other aggressive B-cell lymphomas, ensuring their absence before diagnosis of BLL-11q, since BLL-11q may represent <ref name=":3" /> <ref name=":8" /> <ref>{{Cite journal|last=Grygalewicz|first=Beata|last2=Woroniecka|first2=Renata|last3=Rymkiewicz|first3=Grzegorz|last4=Rygier|first4=Jolanta|last5=Malawska|first5=Natalia|last6=Blachnio|first6=Katarzyna|last7=Bystydzienski|first7=Zbigniew|last8=Borysiuk|first8=Anita|last9=Nowakowska|first9=Beata|date=2020-07-01|title=Genetic progression of post-transplant Burkitt-like lymphoma case with 11q-Gain/Loss and MYC amplification|url=https://www.cancergeneticsjournal.org/article/S2210-7762(20)30236-2/abstract|journal=Cancer Genetics|language=English|volume=245|pages=1–5|doi=10.1016/j.cancergen.2020.05.001|issn=2210-7762|pmid=32531723}}</ref>
*Attend to associated chromosomal and mutational abnormalities of other aggressive B-cell lymphomas, ensuring their absence before diagnosis of BLL-11q, since BLL-11q may represent <ref name=":3" /> <ref name=":8">{{Cite journal|last=Wang|first=Jing|last2=Ma|first2=Li|last3=Guo|first3=Jianghong|last4=Xi|first4=Yanfeng|last5=Xu|first5=Enwei|date=2021-03-16|title=Burkitt-like lymphoma with 11q aberration in a patient with AIDS and a patient without AIDS: Two cases reports and literature review|url=https://www.degruyter.com/document/doi/10.1515/med-2021-0246/html|journal=Open Medicine|language=en|volume=16|issue=1|pages=428–434|doi=10.1515/med-2021-0246|issn=2391-5463|pmc=PMC7967281|pmid=33763601}}</ref> <ref>{{Cite journal|last=Grygalewicz|first=Beata|last2=Woroniecka|first2=Renata|last3=Rymkiewicz|first3=Grzegorz|last4=Rygier|first4=Jolanta|last5=Malawska|first5=Natalia|last6=Blachnio|first6=Katarzyna|last7=Bystydzienski|first7=Zbigniew|last8=Borysiuk|first8=Anita|last9=Nowakowska|first9=Beata|date=2020-07-01|title=Genetic progression of post-transplant Burkitt-like lymphoma case with 11q-Gain/Loss and MYC amplification|url=https://www.cancergeneticsjournal.org/article/S2210-7762(20)30236-2/abstract|journal=Cancer Genetics|language=English|volume=245|pages=1–5|doi=10.1016/j.cancergen.2020.05.001|issn=2210-7762|pmid=32531723}}</ref>
*BLL-11q patients treated with R-CHOP (DLBCL treatment) have a higher risk of relapse than those treated with traditional BL treatment <ref name=":5" /> <ref name=":0" />
*BLL-11q patients treated with R-CHOP (DLBCL treatment) have a higher risk of relapse than those treated with traditional BL treatment <ref name=":5" /> <ref name=":0">{{Cite journal|last=Rymkiewicz|first=Grzegorz|last2=Grygalewicz|first2=Beata|last3=Chechlinska|first3=Magdalena|last4=Blachnio|first4=Katarzyna|last5=Bystydzienski|first5=Zbigniew|last6=Romejko-Jarosinska|first6=Joanna|last7=Woroniecka|first7=Renata|last8=Zajdel|first8=Michalina|last9=Domanska-Czyz|first9=Katarzyna|date=2018-05|title=A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration|url=http://www.nature.com/articles/modpathol2017186|journal=Modern Pathology|language=en|volume=31|issue=5|pages=732–743|doi=10.1038/modpathol.2017.186|issn=0893-3952}}</ref>


Tentatively appears to portend a better prognosis with high likelihood of years of remission <ref name=":6" /> <ref name=":9" /> <ref name=":5" /><ref name=":3" />
Tentatively appears to portend a better prognosis with high likelihood of years of remission <ref name=":6" /> <ref name=":9" /> <ref name=":5" /><ref name=":3" />


*100% 2 year event free survival in pediatric cohort<ref name=":4" />
*100% 2 year event free survival in pediatric cohort<ref name=":4">{{Cite journal|last=Au‐Yeung|first=Rex K. H.|last2=Arias Padilla|first2=Laura|last3=Zimmermann|first3=Martin|last4=Oschlies|first4=Ilske|last5=Siebert|first5=Reiner|last6=Woessmann|first6=Wilhelm|last7=Burkhardt|first7=Birgit|last8=Klapper|first8=Wolfram|date=2020-09|title=Experience with provisional WHO‐entities large B‐cell lymphoma with IRF4 ‐rearrangement and Burkitt‐like lymphoma with 11q aberration in paediatric patients of the NHL‐BFM group|url=https://onlinelibrary.wiley.com/doi/10.1111/bjh.16578|journal=British Journal of Haematology|language=en|volume=190|issue=5|pages=753–763|doi=10.1111/bjh.16578|issn=0007-1048}}</ref>
*
*


[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases H]]
[[Category:HAEM5]]
[[Category:DISEASE]]
[[Category:Diseases H]]
<references />
Retrieved from "https://test.ccga.io/index.php/HAEM5:High_grade_B-cell_lymphoma_with_11q_aberrations"